ArticleCureus2024
Study of Fibrinogen Albumin Ratio in Type 2 Diabetic Patients and Its Correlation With Diabetic Peripheral Neuropathy.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Analysis of Systemic Inflammatory Biomarkers Across Multiple Antiseizure Medications: A Single-Center Retrospective Cohort Study of 1782 Patients.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes mellitus (T2DM) is a chronic metabolic disorder that imposes significant complications, including diabetic peripheral neuropathy (DPN). DPN is characterized by marked inflammation, and the fibrinogen-to-albumin ratio (FAR) is one of the new markers for systemic inflammation, it has been used in various diabetic micro- and macro-vascular complications. The present study investigates the association between FAR and nerve conduction abnormalities in T2DM patients with DPN.
methodsThis was a cross-sectional study conducted on 200 T2DM patients, and 110 (55%) were diagnosed with DPN. Patients were divided into DPN and non-DPN groups. The patient's demographics and the biochemical variables fibrinogen, albumin, and FAR were evaluated and compared among the DPN and non-DPN groups. Nerve conduction studies (NCS) were performed to evaluate motor and sensory nerve functions. Patients were further stratified into FAR tertiles (low, moderate, and high FAR) for subgroup analysis.
resultsThe fibrinogen levels were significantly higher (375.65 ± 35.43 mg/dL vs. 342.87 ± 42.12 mg/dL; p<0.001) and albumin levels were lower (3.12 ± 0.41 g/dL vs. 4.07 ± 0.57 g/dL; p<0.001) in DPN as compared to non-DPN patients. Meanwhile, FAR was higher in DPN as compared to non-DPN patients (120.40 ± 26.32 vs. 84.24 ± 12.87; p<0.001). Further, there was a significant negative correlation for conduction velocities and amplitudes and a positive correlation for latencies with FAR across all nerves tested (p<0.05). In addition, high FAR tertile patients showed lower conduction velocities (peroneal nerve: 35.26 ± 5.82 m/s vs. 42.53 ± 5.34 m/s; p<0.001), reduced amplitudes, and prolonged latencies when compared to moderate and low FAR tertile patients (p<0.05).
conclusionNerve conduction abnormalities in T2DM patients with DPN showed significant association with FAR. Thus, FAR serves as a simple and effective biochemical marker for the assessment of DPN severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.